Innovation in contraception has remained largely unchanged for decades, with limited options available for men.
YourChoice Therapeutics is working to change this with YCT-529, a first-in-class, hormone-free male contraceptive designed to expand choice and redefine reproductive responsibility. Quotient Sciences partnered with the company to support a first-in-human Phase I clinical study of this novel candidate.
YCT-529 works by targeting the retinoic acid receptor-alpha pathway, inhibiting sperm production without the use of hormones, an approach supported by decades of research. Delivered through integrated CRDMO capabilities, Quotient Sciences conducted a Phase 1a program that evaluated safety, tolerability, and pharmacokinetics in healthy volunteers.
“YourChoice Therapeutics recognized that we could deliver more than drug substance and drug product manufacturing,” said Dr. Vanessa Zann, Vice President, Translational Pharmaceutics® and Clinical Pharmacology US at Quotient Sciences.
“Using Translational Pharmaceutics®, we integrated these activities into the trial design and execution, as well—reducing API use, accelerating timelines, and simplifying the supply chain.”
Early findings of YCT-529 demonstrated a favorable safety profile, marking an important milestone in male contraceptive innovation and addressing the need for new family planning options.
Read the full case study to learn about the program, our approach, and how we supported this groundbreaking advancement.
Additionally, you can read peer-reviewed research on the program, “Safety and Pharmacokinetics of the Non-Hormonal Male Contraceptive YCT-529,” featured in Communications Medicine, a Nature Portfolio Journal, July 2025.